Skip to main content

Table 4 Malaria treatment practices reported by populations

From: Attitudes, practices, and determinants of community care-seeking behaviours for fever/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso

 

Children < 5 years

5–15 years

16 years and above

Pregnant women

Total

p-value

Frequency (%)

Frequency (%)

Frequency (%)

Frequency (%)

Frequency (%)

N

462

460

438

34

1394

 

Malaria RDT test performed

 Yes

348 (75.3)

334 (72.6)

285 (65.1)

24 (73.5)

992 (71.2)

 < 0.001

 No

108 (23.4)

126 (27.4)

153 (34.9)

9 (26.5)

396 (28.4)

 

 Unknown

6 (1.3)

0 (0.0)

0 (0.0)

0 (0.0)

6 (0.4)

 

Malaria test result

 Positive

326 (93.7)

330 (98.8)

280 (98.2)

22 (88.0)

958 (96.6)

 < 0.001

 Negative

4 (1.1)

0 (0.0)

3 (1.0)

1 (4.0)

8 (0.8)

 

 Unknown

16 (4.6)

4 (1.2)

1 (0.4)

2 (8.0)

23 (2.3)

 

 Missing data

2 (0.6)

0 (0.0)

1 (0.4)

0

3 (0.3)

 

Treatment receiveda

 Malaria drug

 ACT

319 (71.8)

350 (78.7)

310(75.8)

15(48.4)

994 (74.8)

 < 0.001

 Non-ACT drugb

11 (2.5)

11 (2.5)

21 (5.1)

5 (16.1)

51 (03.8)

 < 0.001

 Artemisinin monotherapyc

15 (03.4)

6 (1.4)

7 (1.7)

5 (16.1)

33 (02.5)

 < 0.001

Non-Malaria drug

 Antipyretics

385 (86.7)

410 (92.1)

375 (91.7)

25 (80.7)

1195 (89.9)

0.01

 Antibiotics

60 (13.5)

30 (6.7)

20 (4.9)

4 (12.9)

114 (23.5)

 < 0.001

 Unknown

17 (03.8)

8 (1.8)

15 (3.7)

2 (6.5)

42 (3.2)

0.31

Name of ACT received

 Artemether-lumefantrine

313 (98.1)

343 (98.3)

304 (98.1)

15 (100.0)

975 (98.2)

0.95

 Other ACTsd

6 (1.9)

6 (1.7)

6 (1.9)

0 (0.0)

18 (1.8)

 

Adherence of duration of treatment with ACT

 1–2 days

25 (7.8)

13 (3.7)

6 (1.9)

1 (6.7)

45 (4.5)

0.01

 3 days

244 (76.5)

295 (84.5)

279 (90.9)

12 (80.0)

830 (83.6)

 

 > 3 days

47 (14.7)

39 (11.2)

22 (7.1)

2 (13.3)

110 (11.1)

 

 Missing information

3 (0.9)

2 (0.6)

3 (1.0)

0

8 (0.8)

 
  1. aMultiple responses (percentages add to more than 100% as some patients had more than one reason of choosing a provider)
  2. bQuinine, sulfadoxine-pyrimethamine
  3. cArtesunate and artemether injectable
  4. dPyronaridine-artesunate or amodiaquine-artesunate or dihydroartemisinin-piperaquine